Skip nav to main content.

Scientists Discover a Key Driver of Alzheimer’s Disease

There is some exciting new research on Alzheimer’s disease. Alzheimer’s-focused drug developer Alzheon is highlighting…

  • August 28, 2018

There is some exciting new research on Alzheimer’s disease.

Alzheimer’s-focused drug developer Alzheon is highlighting the discovery of a substance in the human brain that inhibits the formation of neurotoxic beta amyloid oligomers, which are key drivers of Alzheimer’s disease.

The substance was identified as 3-sulfopropanoic acid (3-SPA), the primary metabolite of tramiprosate and of the company’s prodrug ALZ-801 in humans.

The cognitive improvements observed in AD patients in the tramiprosate Phase 3 studies may be attributed, in part, to the therapeutic effects of 3-SPA in the brain.

This discovery indicates a potential protective role of 3-SPA in aging human brains and in Alzheimer’s disease, and elucidates the beneficial pharmaceutical attributes of the company’s ALZ-801, including a favorable safety profile, selectivity against amyloid oligomers, and excellent brain penetration.

In other words, the company may be on the road to an effective treatment for Alzheimer’s.

The presence of an endogenous substance that can prevent amyloid oligomers formation also suggests the possibility of a protective endogenous anti- amyloid oligomers pathway within the human central nervous system, with the potential to prevent or delay the onset of AD.

Such physiological amyloid oligomers oligomer pathway could modulate the neurotoxic effects of abnormal amyloid oligomers aggregation in the aging human brain.

So, it might be possible to prevent Alzheimer’s disease in aging people. We can’t stress enough that these discoveries may or may not result in effective new drugs in the near future. However, this is some hopeful research.

Leave a Comment